Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2

Status

Completed 6

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Sarcoma 6CNS 6

Conditions

Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Glioblastoma 7Polycythemia Vera 6Gliosarcoma 6Leukemia 5Head and Neck Neoplasms 5Meningioma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Neoplasms 3Myelodysplastic Syndromes 3Laryngeal Neoplasms 3Central Nervous System Neoplasms 3Thrombocythemia, Essential 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Pharyngeal Neoplasms 2Paranasal Sinus Neoplasms 2Oropharyngeal Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Hypopharyngeal Neoplasms 2Glioma 2Congenital Abnormalities 2Carcinoma, Squamous Cell 2Astrocytoma 2

Interventions

Temozolomide 93Radiotherapy 66Bevacizumab 35Radiation 22Carmustine 21Erlotinib Hydrochloride 17Chemotherapy, Adjuvant 17Irinotecan 16Magnetic Resonance Spectroscopy 13Radiotherapy, Conformal 11O(6)-benzylguanine 11Surgical Procedures, Operative 10Radiotherapy, Intensity-Modulated 10sargramostim 9Sirolimus 9Imatinib Mesylate 9Carboplatin 9temsirolimus 8motexafin gadolinium 7Thalidomide 7Gene Expression Profiling 7aldesleukin 6Sorafenib 6Radiosurgery 6Immunohistochemistry 6Hydroxyurea 6Gefitinib 6Filgrastim 6Everolimus 6Etoposide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Gliosarcoma × Hydroxyurea × Clear all
NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00019058 2015-04-29

Radiation Therapy in Treating Patients With Glioblastoma

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00615927 2013-03-15

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Duke University

Phase 2 Completed
64 enrolled 9 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00613132 2013-02-20

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Duke University

Phase 1 Completed
78 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00354913 2013-01-18

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Duke University

Phase 2 Completed
21 enrolled 8 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Meningioma, Gliosarcoma

NCT00613054 2012-12-05

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Duke University

Phase 1 Completed
27 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡